Most preterm newborns are managed by ad hoc use phototherapy to reverse hyperbilirubinemia with the intent to prevent bilirubin neurotoxicity. A precise threshold-based relationship between specific total bilirubin levels and intervention has been elusive. This is most likely due to other biomarkers such as hemolysis, developmental maturation, concurrent illnesses, or even interventions, may impede bilirubin/albumin binding. The over- prescription of phototherapy has impacted clinical and family-centered care, and in the extreme preterm infants, it may have augmented their risk of mortality. Thus, the opportunity to precisely individualize phototherapy in order to reduce its prescription is unique. We have assembled a transdisciplinary team to examine critical unanswered questions including the postnatal role of bilirubin binding capacity (BBC) in the context of clinical modifiers and antecedents for a domain of recently reported bilirubin-induced neurologic disorders that includes neuro-anatomical, hearing, visual and developmental processing impairments. In this study, we will evaluate two new innovative nanotechniques to quantify bilirubin load for the first time in the context of a clinical decision algorithm to identify those most at risk for any bilirubn-related neurotoxicity. We anticipate that knowledge gained from this study will lead to ethically testable hypotheses to prescribe phototherapy with precision.

Public Health Relevance

Bilirubin binding capacity (BBC), based on recent data determined in our NIH-SBIR Phase II study strongly suggests a testable concept that could lead to 'individualized parameters to prescribe phototherapy' in preterm neonates. To this end, we propose to build on the evidence that BBC, a biomarker of insufficient bilirubin bind- ing, alone or in combination with phenotypic biomarkers of bilirubin production are objective clinical correlates of early-onset bilirubin neurotoxicity and can be individualized and applied to target precise thresholds for treatment with phototherapy and exchange transfusion in preterm infants.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HD082319-01A1
Application #
9025399
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Krotoski, Danuta
Project Start
2015-12-01
Project End
2017-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Stanford University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304